Abnormal lower limb muscle activity is the most common cause of the alterative pattern of gait in stroke survivors, resulting from spastic and paralytic muscles around the hip, knee, and ankle joints. However, the activity of the major lower limb muscles that control the legs to facilitate walking in stroke patients have not been clearly understood in each subphase of the gait. This study differentiated the characteristics of surface electromyography (sEMG) signals of lower limb muscles during four subphases of gait cycle between stroke patients and healthy subjects. Sixteen chronic stroke patients and sixteen healthy subjects were recruited. All participants completed three walking trials with a self-selected walking speed. The sEMG signals were recorded on the gluteus medius, rectus femoris, long head of biceps femoris, medial gastrocnemius, tibialis anterior, and peroneus longus muscles. The characteristics of sEMG signals were processed and analyzed in the time and frequency features, considering the first double support, single support, second double support, and swing phases of the gait cycle.The stroke patients had altered sEMG characteristics on both paretic and non-paretic sides compared to healthy subjects across the sub-phases of gait cycle for all six muscles. All time domain features of sEMG signal showed that the medial gastrocnemius muscle has the most significant impaired activity ( < 0.05) and affected gait disturbance during all four subphases of the gait cycle. The findings demonstrated that the medial gastrocnemius muscle had impaired activity and was most affected during all four sub-phases of the gait cycle. This indicates that sEMG of medial gastrocnemius muscle can be used to measure the improvement of gait rehabilitation.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11569779 | PMC |
http://dx.doi.org/10.7717/peerj.18473 | DOI Listing |
Alzheimers Dement
December 2024
NYU Grossman School of Medicine, New York, NY, USA; NYU, New York City, NY, USA.
Background: Astrocytes, a major glial cell in the central nervous system (CNS), can become reactive in response to inflammation or injury, and release toxic factors that kill specific subtypes of neurons. Over the past several decades, many groups report that reactive astrocytes are present in the brains of patients with Alzheimer's disease, as well as several other neurodegenerative diseases. In addition, reactive astrocyte sub-types most associated with these diseases are now reported to be present during CNS cancers of several types.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Dementia Research Centre, UCL Queen Square Institute of Neurology, London, United Kingdom.
The recent positive phase 3 clinical trials of new treatments and their licensing and roll-out in the US and other countries represents a major turning point in Alzheimer's disease research. As has been the case with many other diseases, e.g.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Universidad Autónoma de San Luis Potosi, San Luis Potosi, SL, Mexico.
Background: Alzheimer's Disease (AD) is a neurodegenerative disease, characterized by a decrease in cognitive and behavioral functions of patients. Between the multiple potential disease-modifying therapeutics for AD, we have monoclonal antibodies as aducanumab, lecanemab, and donanemab. Recent results from the TRAILBLAZER-ALZ trial, highlighted donanemab as a promising monoantibodies treatment of early symptomatic AD.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Siemens Heathineers, Princeton, NJ, USA.
Background: The recent breakthrough in monoclonal antibody treatment for Alzheimer's disease (AD) has ushered in a new phase in AD healthcare. However, associated amyloid-related imaging abnormalities (ARIA) present a significant risk to patients, necessitating careful monitoring. Detection by radiologists can be challenging and may suffer from inconsistency.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
The Bedford VA Research Corporation, Inc., Bedford, MA, USA.
Background: Cerebral amyloid angiopathy (CAA) is a significant contributor to hemorrhagic stroke, notably lobar intracerebral hemorrhage (ICH) and convexity subarachnoid hemorrhage (SAH), both of which have been observed in patients with MCI/AD. To evaluate all-cause mortality among veterans with mild cognitive impairment (MCI) and Alzheimer's dementia (AD) with/without Intracerebral hemorrhage and subarachnoid hemorrhage (ICH/SAH) in the United States (US) Veterans Affairs Healthcare System (VAHS).
Method: Veterans with MCI or AD were identified based on having clinical notes or diagnostic codes in the VAHS database (2010-2019).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!